Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.55 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.49 |
| ▸ | MITF | O75030 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HTR1E | P28566 | 1/20 | 0.44 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30982183 | 0.88 | KMT2A (0.63) | MEN1KMT2APKMCTDSP1FFAR1 | |
| SCHEMBL27536627 | 0.84 | FFAR1 (0.47) | MEN1KMT2APKMCTDSP1FFAR1 | |
| SCHEMBL8007377 | 0.83 | FFAR1 (0.69) | MEN1KMT2APKMCTDSP1FFAR1 | |
| SCHEMBL30982192 | 0.83 | KMT2A (0.57) | MEN1KMT2APKMCTDSP1FFAR1 | |
| SCHEMBL7194995 | 0.80 | PKM (0.56) | MEN1KMT2APKMCTDSP1FFAR1 | |
| SCHEMBL16191249 | 0.78 | PKM (0.68) | MEN1KMT2APKMCTDSP1MITF | |
| SCHEMBL14415599 | 0.78 | PKM (0.59) | MEN1KMT2APKMCTDSP1MITF | |
| SCHEMBL9237527 | 0.78 | PKM (0.59) | MEN1KMT2APKMCTDSP1FFAR1 | |
| SCHEMBL966816 | 0.78 | MEN1 (0.58) | MEN1KMT2APKMCTDSP1FFAR1 | |
| SCHEMBL8007179 | 0.77 | KMT2A (0.67) | MEN1KMT2APKMCTDSP1FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3197879-B1 | NEW BICYCLIC DERIVATIVES HAVING BETA2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES | ALMIRALL SA (ES) | 2020-02-26 | — | — | EP | disclosed |
| EP-3197879-A1 | NEW BICYCLIC DERIVATIVES HAVING BETA2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES | Almirall S.A. (ES) | 2017-08-02 | — | — | EP | disclosed |
| WO-2016046390-A1 | NEW BICYCLIC DERIVATIVES HAVING BETA2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES | ALMIRALL, S.A. (ES) | 2016-03-31 | — | — | WO | disclosed |
| US-7301045-B2 | Method for preparing ester condensate | JAPAN SCIENCE AND TECHNOLOGY CORPORATION (JP) | 2007-11-27 | — | — | US | disclosed |
| EP-1334960-B1 | METHOD FOR PREPARING ESTER CONDENSATE | JAPAN SCIENCE & TECH AGENCY (JP) | 2006-10-11 | — | — | EP | disclosed |
| US-20040015005-A1 | Process for producing esterificated condensate | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2004-01-22 | — | — | US | disclosed |
| EP-1334960-A1 | PROCESS FOR PRODUCING ESTERIFICATED CONDENSATE | Japan Science and Technology Corporation (JP) | 2003-08-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040015005-A1 | Process for producing esterificated condensate | HACL2, ADH5, ADH1C | MEN1 4132/4885KMT2A 3996/4885PKM 2500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.